Kidd Information and Courses from MediaLab, Inc.
These are the MediaLab courses that cover Kidd and links to relevant pages within the course.
Learn more about laboratory continuing education for medical technologists to earn CE credit for AMT, ASCP, NCA, and state license renewal and recertification. Or get information about laboratory safety and compliance courses that deliver cost-effective OSHA safety training and continuing education to your laboratory's employees.
| When to Use an Enzyme Panel If multiple antibodies are present and your selection of antibody panel cells is limited, performing an enzyme panel will give you more information as to which antibodies might be present. The benefit of using an enzyme panel is that enzymes will enhance some antigens and destroy other antigens. This makes it easier to narrow your choice of potential antibodies. However, you cannot use enzyme panel cells as the only rule-out cells because of the fact that some of the antigens are destroyed and you may not pick up an antibody that is present. Antigens enhanced: Rh, Kidd, Lewis, P1, I, and ABOAntigens destroyed: Duffy, MNS, XgaExample: You suspect an e and a Fyb and have already identified a D. By performing an enzyme panel, the e and D would be enhanced (strong reaction) and the Fyb would be destroyed (no reaction). Cell Number D e Fyb AHG 2 + 0 0 4+ 4 0 + 0 4+ 6 0 0 + 0 | View Page |
| When to Suspect Dosage Suspect dosage if varying strengths in reactivity are seen and reactions are in the same phase. Weaker reactions will be seen if suspected antibody is reacting with antigens in the heterozygous state. Stronger reactions are seen if the antigen is present on the testing cells in the homozygous state. This allows more corresponding antibody to bind with the antigen. Remember the antibodies known for showing dosage are: Rh, Kidd, Duffy, MNSs, and Lutheran. Dosage may be seen if cells are R2R2 (DcE/DcE). These red cells have more D antigen sites so reaction with anti-D may be stronger.Refer to Example 5 on the following page. | View Page |
| Immune Antibodies Immune antibodies occur in the serum of individuals who become sensitized to foreign antigens through pregnancy or transfusion. IgM predominates in the primary response, IgG in the secondary response. Most react at 37°C and are considered clinically significant. Examples include antibodies in the Kell, Rh, Duffy, and Kidd systems. Immune antibodies can be classified as alloantibodies or autoantibodies.Alloantibodies Produced by exposure to foreign red cell antigens which are non-self antigens but are of the same species. They react only with allogenic cells. Exposure occurs through pregnancy or transfusion. Examples include anti-K and anti-E. Autoantibodies Produced in an autoimmune process and directed against one's own red cell antigens. React with patient's own cells and all cells tested. Can possibly mask the presence of other significant antibodies. It is very important to make sure that no underlying significant antibodies are present if an autoantibody is suspected. A positive direct antiglobulin test (DAT) or auto control could indicate the presence of an autoantibody. Examples include cold auto (P or I) or warm auto (Rh specificity). | View Page |
| Products Used to Facilitate Antibody Identification Monospecific anti-human globulin (IgG) enables sensitized red cells to cross-link so that agglutination is visible.Enhancement media are sometimes used to further promote agglutination and reduce incubation time. Low ionic strength saline (LISS) is the most common enhancement media. LISS reduces the ionic strength in the testing sample and causes reduction of the zeta potential. It increases antibody uptake and decreases incubation time. Polyethylene Glycol (PEG): brings red blood cells (RBCs) closer together and concentrates antibodies by removing water molecules from the testing sample. It is the most sensitive of the enhancement media; strengthening almost all clinically significant antibodies. However, it will also enhance some clinically insignificant antibodies as well. Centrifugation should be avoided when PEG is used. PEG can cause aggregates to form if the sample (red cell - serum mixture) with PEG added is centrifuged. Reaction readings should only be done at the AHG phase. 22% Albumin: reduces zeta potential, bringing the RBCs closer together and enhancing agglutination. Albumin does not contribute much to antibody uptake. Longer incubation time is needed with this media than with the previously discussed media. Detection of some IgG antibodies can be enhanced with enzyme test methods. Proteolytic enzymes (papain and ficin) denature some RBC antigens and remove negative charges from the RBC membranes. This reduces the zeta potential, bringing the cells closer together. Enzyme techniques are particularly useful in the identification of Rh antibodies and antibodies in the Kidd, Lewis, P and I systems. However, enzymes destroy some antigens including Fya, Fyb, M, and N. The effect of proteolytic enzymes on the S and s antigens are variable. | View Page |
| A delayed hemolytic transfusion reaction is most likely to be the result of which of the following antibodies: | View Page |
| Which of the following blood group antigen-antibody reactions is enhanced by using enzymes: | View Page |
| Proteolytic enzyme techniques may be useful in identifying which of the following antigen groups: | View Page |
| Evaluating inconsistencies Once an antibody has been identified and other clinically significant antibodies have been excluded, the case must be looked at as a whole to confirm the logical consistency of all results and data.This process includes assessing any inconsistencies.For example:1. Is the patient negative for the corresponding antigen? Yes: The patient is Jk(a-).2. Is the antibody specificity consistent with the typical phase(s) of reactivity for the antibody? Yes: Kidd antibodies are IgG and react in the antiglobulin phase. | View Page |
| Antibody investigation Immediate post-transfusion antibody identification results Cell Rh Rhesus Kell Duffy Kidd MNSs P Lewis Lu Results1 Results2 C D E c e Cw K k Kpa Fya Fyb Jka Jkb M N S s P1 Lea Leb Lua Gel IAT Gel IAT 1 rr 0 0 0 + + 0 0 + 0 + 0 + 0 0 + + + +S + 0 0 0 w+ 2 rr 0 0 0 + + 0 0 + 0 0 + + + 0 + + + +S + 0 0 0 0 3 rr 0 0 0 + + 0 0 + 0 + 0 0 + 0 + + 0 + 0 + 0 0 0 4 r"r 0 0 + + + 0 0 + 0 + + 0 + 0 + 0 + + + 0 0 0 0 5 R2R2 0 + + + 0 0 + 0 0 + 0 + + + 0 + 0 + 0 | View Page |
| Investigating weak antibodies In this case the patient's antibody has disappeared from the plasma by adsorbing to transfused donor red cells. It is detectable but unidentifiable in the post-transfusion red cell eluate. Several trial and error procedures exist to enhance weak antibodies. Which methods will enhance the reactivity of a given antibody depend on its characteristics. Methods to investigate weak antibodies include: Use a higher plasma to red cell ratio (add more antibody-containing plasma or eluate) Increase incubation time (if consistent with manufacturer instructions, if applicable) Use enzyme-treated panel red cells (enzymes enhance IgG antibodies in Rh and Kidd blood systems but denature some antigens, e.g., Fya, Fyb, S) Try alternative antibody detection methods, e.g., if using LISS routinely, try polyethylene glycol (PEG) or column agglutination methods such as gel, providing they have been validated for use in the TS laboratory. | View Page |
| Antibody identification (2 weeks post-transfusion) Fortunately, the patient's condition stabilized and additional transfusions were not required. Two weeks later, new patient specimens were drawn for antibody studies. Antibody identification results Cell Rh Rhesus Kell Duffy Kidd MNSs P Lewis Lu Results Cell C D E c e Cw K k Kpa Fya Fyb Jka Jkb M N S s P1 Lea Leb Lua Gel IAT* 1 rr 0 0 0 + + 0 0 + 0 + 0 + 0 0 + + + +S + 0 0 1+ 1 2 rr 0 0 0 + + 0 0 + 0 + 0 + + 0 + + + +S + 0 0 w+ 2 3 rr 0 0 0 + + 0 0 + 0 + + 0 + 0 + + 0 + 0 + 0 0 3 4 r"r 0 0 + + + 0 0 + 0 + + 0 + 0 + 0 + + + 0 0 0 4 5 R2R2 0 + + + 0 0 + 0 0 + + + + + 0 + 0 + 0 | | View Page |
| When the patient's plasma was non-reactive with panel cells, and very weak and unidentifiable in the post-transfusion RBC eluate, no attempt was made to try to enhance the weak antibodies.We now know that the patient has anti-Jka and that it disappeared rapidly from the patient's plasma after transfusion with two group O Rh-negative RBC. Consider the question below, then click on the question to receive the answer. | View Page |
| DAT change of status Notice that the patient's DAT is now negative (IAT autocontrol in the panel done 2-weeks post-transfusion is negative). Cell Rh Rhesus Kell Duffy Kidd MNSs P Lewis Lu Results Cell C D E c e Cw K k Kpa Fya Fyb Jka Jkb M N S s P1 Lea Leb Lua Gel IAT* 1 rr 0 0 0 + + 0 0 + 0 + 0 + 0 0 + + + +S + 0 0 1+ 1 2 rr 0 0 0 + + 0 0 + 0 + 0 + + 0 + + + +S + 0 0 w+ 2 3 rr 0 0 0 + + 0 0 + 0 + + 0 + 0 + + 0 + 0 + 0 0 3 4 r"r 0 0 + + + 0 0 + 0 + + 0 + 0 + 0 + + + 0 0 0 4 5 R2R2 0 + + + 0 0 + 0 0 + + + + + 0 + 0 + 0 + 0 w+ 5 6 | View Page |